NASDAQ:GTHX G1 Therapeutics (GTHX) Stock Price, News & Analysis $3.91 -0.04 (-1.01%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$3.84▼$4.0650-Day Range$2.20▼$4.5552-Week Range$1.08▼$6.14Volume491,145 shsAverage Volume1.41 million shsMarket Capitalization$204.41 millionP/E RatioN/ADividend YieldN/APrice Target$4.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get G1 Therapeutics alerts: Email Address G1 Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.50 Rating ScoreUpside/Downside2.3% Upside$4.00 Price TargetShort InterestBearish13.45% of Shares Sold ShortDividend StrengthN/ASustainability-2.45Upright™ Environmental ScoreNews Sentiment0.82Based on 5 Articles This WeekInsider TradingSelling Shares$55,000 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.50) to ($0.22) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.83 out of 5 starsMedical Sector677th out of 936 stocksPharmaceutical Preparations Industry313th out of 436 stocks 1.3 Analyst's Opinion Consensus RatingG1 Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 3 buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageG1 Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about G1 Therapeutics' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted13.45% of the outstanding shares of G1 Therapeutics have been sold short.Short Interest Ratio / Days to CoverG1 Therapeutics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in G1 Therapeutics has recently increased by 23.55%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldG1 Therapeutics does not currently pay a dividend.Dividend GrowthG1 Therapeutics does not have a long track record of dividend growth. Previous Next 3.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreG1 Therapeutics has received a 49.69% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Detoxifying agents for antineoplastic treatment (V03AF)" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for G1 Therapeutics is -2.45. Previous Next 3.2 News and Social Media Coverage News SentimentG1 Therapeutics has a news sentiment score of 0.82. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for G1 Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 5 people have searched for GTHX on MarketBeat in the last 30 days. This is a decrease of -38% compared to the previous 30 days.MarketBeat Follows6 people have added G1 Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, G1 Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $55,000.00 in company stock.Percentage Held by InsidersOnly 6.11% of the stock of G1 Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 24.21% of the stock of G1 Therapeutics is held by institutions.Read more about G1 Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for G1 Therapeutics are expected to grow in the coming year, from ($0.50) to ($0.22) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of G1 Therapeutics is -6.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of G1 Therapeutics is -6.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioG1 Therapeutics has a P/B Ratio of 5.75. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about G1 Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad WealthPressThis TSLA short trade is on a nine win hot streakMost Tesla Shareholders are disappointed in the stock's performance in 2024. Year to date, it's down 30%... And things don’t seem to be getting better. That said, one professional trader has found a way to turn Tesla’s demise into a flurry of opportunity… In fact, he has not lost a single trade on Tesla this year. As of this mailing he’s 9 for 9 with incredible wins under his belt. Just see for yourself.But I can promise that you’ll see all the details for yourself here. About G1 Therapeutics Stock (NASDAQ:GTHX)G1 Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing Trilaciclib that is in Phase 3 clinical trial for 1L metastatic triple negative breast cancer (mTNBC); and Phase 2 clinical trial as an antibody-drug conjugate combination trial in mTNBC, as well as completed Phase 2 clinical trial for Neoadjuvant TNBC and 1L Bladder cancer. The company has a license agreement with Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat various indication in humans; Incyclix for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses; and Simcere Pharmaceutical Co., Ltd for the development and commercialization of trilaciclib in all indications. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.Read More GTHX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart GTHX Stock News HeadlinesJuly 9, 2024 | insidertrades.comJohn E. (Jack) Jr. Bailey Sells 7,662 Shares of G1 Therapeutics, Inc. (NASDAQ:GTHX) StockJuly 26 at 4:17 PM | finance.yahoo.comG1 Therapeutics, Inc.'s (NASDAQ:GTHX) top owners are retail investors with 56% stake, while 28% is held by institutionsJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.July 25 at 11:15 AM | globenewswire.comG1 Therapeutics to Release Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024July 15, 2024 | investorplace.comG1 Therapeutics Stock: The Undervalued Gem Poised for a 30% Revenue Surge by 2025July 10, 2024 | investorplace.comBiotech Bombshell: G1 Therapeutics Stock Is Too Much of a GambleJuly 10, 2024 | investorplace.comBiotech Bombshell: G1 Therapeutics Stock Is Too Much of a GambleJuly 1, 2024 | globenewswire.comG1 Therapeutics Added to the Russell 2000® and 3000® IndexesJuly 26, 2024 | American Hartford Gold Group (Ad)Prepare for a Recession Unlike Any OtherDave Ramsey Is Dangerously Wrong And Here’s Why>> Asked whether we’re on the cusp of a US Dollar crash, Dave Ramsey made a stunning miscalculation while live on air: “Am I worried about this? Absolutely not.” Frankly, I've never seen someone so confident in being wrong… Because what’s happening to the US Dollar is not something you should “keep an eye on”… But instead, is an imminent threat you should get ahead of right NOW.June 24, 2024 | investorplace.comWhy Is G1 Therapeutics (GTHX) Stock Down 56% Today?June 24, 2024 | globenewswire.comG1 Therapeutics Provides Update on Phase 3 PRESERVE 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer (mTNBC)June 5, 2024 | globenewswire.comG1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 28, 2024 | markets.businessinsider.comBuy Rating Affirmed: G1 Therapeutics’ Cosela Shows Significant Survival Benefits in mTNBCMay 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for G1 Therapeutics Amid Promising Clinical OutcomesMay 28, 2024 | msn.comG1 Therapeutics slips after new breast cancer data for lead assetMay 28, 2024 | globenewswire.comMeaningful Improvement in Overall Survival (OS) and Tolerability Observed in Patients Receiving Trilaciclib in Combination with a TROP2 Antibody-Drug Conjugate (ADC)May 24, 2024 | markets.businessinsider.comStrategic Licensing Agreements and Revenue Forecast Uphold Buy Rating for G1 TherapeuticsMay 23, 2024 | globenewswire.comG1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology (ASCO) MeetingSee More Headlines Receive GTHX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for G1 Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today7/26/2024Next Earnings (Confirmed)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GTHX CUSIPN/A CIK1560241 Webwww.g1therapeutics.com Phone(919) 213-9835Fax919-741-5830Employees170Year FoundedN/APrice Target and Rating Average Stock Price Target$4.00 High Stock Price Target$6.00 Low Stock Price Target$3.00 Potential Upside/Downside+2.3%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($0.62) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-47,970,000.00 Net Margins-36.40% Pretax Margin-32.69% Return on Equity-74.75% Return on Assets-24.25% Debt Debt-to-Equity Ratio1.34 Current Ratio2.94 Quick Ratio2.55 Sales & Book Value Annual Sales$82.51 million Price / Sales2.48 Cash FlowN/A Price / Cash FlowN/A Book Value$0.68 per share Price / Book5.75Miscellaneous Outstanding Shares52,280,000Free Float49,087,000Market Cap$204.41 million OptionableOptionable Beta1.53 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. John E. Bailey Jr. (Age 59)CEO, President & Director Comp: $1.06MMr. Mark Avagliano (Age 48)Chief Business Officer Comp: $628.54kMr. John W. Umstead V (Age 39)Chief Financial Officer Mr. Terry L. Murdock (Age 64)Chief Operating Officer Comp: $541.59kMr. William C. Roberts (Age 55)Vice President of Investor Relations & Corporate Communications Ms. Monica R. ThomasGeneral Counsel & Chief Compliance OfficerMr. Evan Hicks M.B.A.Vice President of MarketingDr. Rajesh K. Malik Ch.B. (Age 65)M.B., M.D., Chief Medical Officer Comp: $596.37kMr. Andrew Perry (Age 51)Chief Commercial Officer Comp: $568.6kMr. Jeff MacdonaldSenior Director of Investor Relations & Corporate CommunicationsMore ExecutivesKey CompetitorsRigel PharmaceuticalsNASDAQ:RIGLEvolusNASDAQ:EOLSWave Life SciencesNASDAQ:WVEPhibro Animal HealthNASDAQ:PAHCStoke TherapeuticsNASDAQ:STOKView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 133,230 shares on 7/26/2024Ownership: 0.255%Raymond James & AssociatesSold 5,158 shares on 7/19/2024Ownership: 1.526%SG Americas Securities LLCBought 33,588 shares on 7/12/2024Ownership: 0.090%John E (Jack) Jr. BaileySold 7,662 sharesTotal: $19,231.62 ($2.51/share)John W V UmsteadSold 527 sharesTotal: $1,322.77 ($2.51/share)View All Insider TransactionsView All Institutional Transactions GTHX Stock Analysis - Frequently Asked Questions How have GTHX shares performed this year? G1 Therapeutics' stock was trading at $3.05 at the beginning of 2024. Since then, GTHX stock has increased by 28.2% and is now trading at $3.91. View the best growth stocks for 2024 here. How were G1 Therapeutics' earnings last quarter? G1 Therapeutics, Inc. (NASDAQ:GTHX) issued its quarterly earnings results on Wednesday, May, 1st. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.19) by $0.01. The firm earned $14.48 million during the quarter, compared to the consensus estimate of $15.21 million. G1 Therapeutics had a negative net margin of 36.40% and a negative trailing twelve-month return on equity of 74.75%. When did G1 Therapeutics IPO? G1 Therapeutics (GTHX) raised $101 million in an initial public offering on Wednesday, May 17th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. J.P. Morgan and Cowen and Company acted as the underwriters for the IPO and Needham & Company and Wedbush PacGrow were co-managers. Who are G1 Therapeutics' major shareholders? Top institutional shareholders of G1 Therapeutics include Raymond James & Associates (1.53%), Bank of New York Mellon Corp (0.25%), SG Americas Securities LLC (0.09%) and Concourse Financial Group Securities Inc.. Insiders that own company stock include John E (Jack) Jr Bailey, John W V Umstead, Rajesh Malik, Terry L Murdock, Mark A Velleca, Andrew Perry, Monica R Thomas, Jennifer K Moses and James S Hanson. View institutional ownership trends. How do I buy shares of G1 Therapeutics? Shares of GTHX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of G1 Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that G1 Therapeutics investors own include Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), ImmunoGen (IMGN), Inovio Pharmaceuticals (INO), Johnson & Johnson (JNJ), Gilead Sciences (GILD) and Kadmon (KDMN). This page (NASDAQ:GTHX) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding G1 Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share G1 Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free GTHX Stock Alerts